Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia

Journal of Clinical Psychiatry

Volumn 64, Issue 3, 2003, Pages 316-320

  Lane, Hsien Yuan ^a   Chang, Yue Cune ^b,d   Cheng, Yiao Cheung ^c   Liu, Guang Chyi ^c   Lin, Xing Ru ^d   Chang, Wen Ho ^b,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAMKANG UNIVERSITY   (Taiwan)

^c HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; LORAZEPAM; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COGNITION; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL INTERACTION; TREATMENT OUTCOME;

EID: 0037362363     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0314     Document Type: Article

References (49)

1. Meltzer HY, Fleischhacker WW. Weight gain: a growing problem in schizophrenia management [introduction]. J Clin Psychiatry 2001;62(suppl 7):3
2. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(suppl 23):5-12
3. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
4. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-238
5. Planansky K. Changes in weight in patients receiving a "tranquilizing" drug. Psychiatr Q 1958;32:289-303
6. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363
7. 2c serotonin receptors. Nature 1995;374:542-546
8. 1) affects food intake in rats. J Nutr 1994;124:1029-1036
9. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62(suppl 23):45-66
10. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(suppl B):157-160
11. Wetterling T, Müßígbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-321
12. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-440
13. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry 1998;43:520-524
14. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72
15. Lamberti JS. Is antipsychotic drug-induced weight gain associated with a favorable clinical response? [letter] J Clin Psychiatry 2000;61:678
16. Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-819
17. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60(suppl 21):20-24
18. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62(suppl 2):41-44
19. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
20. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995;15 (suppl 1):2-3
21. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369
22. Lane H-Y, Chiu W-C, Chou JC-Y, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61:209-214
23. Lane H-Y, Chang W-H, Chin C-C, et al. A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia [letter]. J Clin Psychiatry 2001;62:994-995
24. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998;8:151-159
25. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000;10:259-268
26. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001;62:114-116
27. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:828-835
28. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
29. Collaborative Working Group on Clinical Trial Evaluations. Clinical development of atypical antipsychotics: research design and evaluation. J Clin Psychiatry 1998;59(suppl 12):10-16
30. Lane H-Y, Chang W-H. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. J Clin Psychiatry 1999;60:487-488
31. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
32. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-187
33. Lane H-Y, Chang W-H. Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter with reply] J Clin Psychiatry 1998;59:430-431
34. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-476
35. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five factor model of schizophrenia: initial validation. J New Ment Dis 1994;182:631-638
36. Honigfeld G, Klett G. The Nurses' Observation Scale for Inpatient Evaluation: a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71
37. Tsai G, Yang P, Chung LC, et al. D-Serine added to antipsychotic for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-1089
38. Tsai G, Young P, Chung LC, et al. D-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-1825
39. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796
40. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
41. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive ration scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
42. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
43. SAS Institute Inc. SAS OnlineDoc(R), Version 8. Cary, NC: SAS Institute Inc; 1999
44. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
45. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000;101:416-432
46. Lane H-Y, Liu C-C, Chang W-H. Risperidone for exclusively negative symptoms [letter]. Am J Psychiatry 1999;156:335
47. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222
48. Ballus C. Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia. Schizophr Res 1997;28:247-255
49. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(suppl 9):5-9